XOMA (NASDAQ:XOMA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $104.00 target price on the biotechnology company’s stock.

Separately, StockNews.com raised shares of XOMA from a “sell” rating to a “hold” rating in a research note on Friday, March 21st.

XOMA Stock Performance

Shares of XOMA stock opened at $20.33 on Friday. XOMA has a fifty-two week low of $19.92 and a fifty-two week high of $35.00. The stock’s 50-day moving average is $23.76 and its two-hundred day moving average is $26.89. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The firm has a market cap of $243.53 million, a P/E ratio of -5.84 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The firm had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. Analysts predict that XOMA will post -1.41 earnings per share for the current fiscal year.

Insider Activity at XOMA

In other news, CIO Bradley Sitko bought 4,134 shares of the stock in a transaction that occurred on Friday, March 21st. The shares were acquired at an average cost of $23.89 per share, for a total transaction of $98,761.26. Following the purchase, the executive now owns 10,484 shares of the company’s stock, valued at $250,462.76. This represents a 65.10 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 4,747 shares of company stock valued at $114,544. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Several hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its holdings in shares of XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares during the last quarter. New York State Common Retirement Fund increased its position in XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 800 shares during the period. Wells Fargo & Company MN raised its stake in XOMA by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 1,183 shares during the last quarter. Bank of America Corp DE boosted its holdings in XOMA by 34.7% in the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,009 shares during the period. Finally, Los Angeles Capital Management LLC bought a new stake in XOMA in the 4th quarter valued at $206,000. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.